1. Outcomes of Advanta V12 Covered Stents After Fenestrated Endovascular Aneurysm Repair
- Author
-
Claire van der Riet, Jean-Paul P.M. de Vries, Richte C.L. Schuurmann, Reinoud P H Bokkers, Ignace F.J. Tielliu, Athanasios Katsargyris, Clark J. Zeebregts, Eric L.G. Verhoeven, Man, Biomaterials and Microbes (MBM), Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Robotics and image-guided minimally-invasive surgery (ROBOTICS), and Multi-Modality Medical Imaging
- Subjects
medicine.medical_specialty ,Time Factors ,medicine.medical_treatment ,Clinical Investigations ,Prosthesis Design ,Endovascular aneurysm repair ,Blood Vessel Prosthesis Implantation ,abdominal aortic aneurysm ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Endovascular treatment ,Covered stent ,Aged ,Retrospective Studies ,Aged, 80 and over ,stent-graft ,business.industry ,Endovascular Procedures ,endograft ,Middle Aged ,PERFORMANCE ,medicine.disease ,Abdominal aortic aneurysm ,Surgery ,Blood Vessel Prosthesis ,Treatment Outcome ,endovascular aortic aneurysm repair ,Stents ,GRAFTS ,Cardiology and Cardiovascular Medicine ,business ,balloon-expandable covered stent ,Aortic Aneurysm, Abdominal - Abstract
Purpose: Fenestrated endovascular aneurysm repair (FEVAR) is a well-established endovascular treatment option for pararenal abdominal aortic aneurysms in which balloon-expandable covered stents (BECS) are used to bridge the fenestration to the target vessels. This study presents midterm clinical outcomes and patency rates of the Advanta V12 BECS used as a bridging stent. Methods: All patients treated with FEVAR with at least 1 Advanta V12 BECS were included from 2 large-volume vascular centers between January 2012 and December 2015. Primary endpoints were freedom from all-cause reintervention, and freedom from BECS-associated complications and reintervention. BECS-associated complications included significant stenosis, occlusion, type 3 endoleak, or stent fracture. Secondary endpoints included all-cause mortality in-hospital and during follow-up. Results: This retrospective study included 194 FEVAR patients with a mean age of 72.2±8.0 years. A total of 457 visceral arteries were stented with an Advanta V12 BECS. Median (interquartile range) follow-up time was 24.6 (1.6, 49.9) months. The FEVAR procedure was technically successful in 93% of the patients. Five patients (3%) died in-hospital. Patient survival was 77% (95% CI 69% to 84%) at 3 years. Freedom from all-cause reintervention was 70% (95% CI 61% to 78%) at 3 years, and 33% of all-cause reinterventions were BECS associated. Complications were seen in 24 of 457 Advanta V12 BECSs: type 3 endoleak in 8 BECSs, significant stenosis in 4 BECSs, occlusion in 6 BECSs, and stent fractures in 3 BECSs. A combination of complications occurred in 3 BECSs: type 3 endoleak and stenosis, stent fracture and stenosis, and stent fracture and occlusion. The freedom from BECS-associated complications for Advanta V12 BECSs was 98% (95% CI 96% to 99%) at 1 year and 92% (95% CI 88% to 95%) at 3 years. The freedom from BECS-associated reinterventions was 98% (95% CI 95% to 100%) at 1 year and 94% (95% CI 91% to 97%) at 3 years. Conclusion: The Advanta V12 BECS used as bridging stent in FEVAR showed low complication and reintervention rates at 3 years. A substantial number of FEVAR patients required a reintervention, but most were not BECS related.
- Published
- 2021
- Full Text
- View/download PDF